Stratasys Reports Q1 Loss, Reiterates Full-Year Guidance Amid Revenue Decline and Strategic Wins

summarizeSummary

Stratasys Ltd. reported a Q1 2026 GAAP net loss of $23.8 million and a non-GAAP net loss of $1.3 million, with revenue declining 2.4% year-over-year, but reaffirmed its full-year 2026 financial outlook.

check_boxKey Events

• Q1 Financial Performance Declines

  Revenue for Q1 2026 decreased 2.4% year-over-year to $132.7 million. The company reported a GAAP net loss of $23.8 million, widening from $13.1 million in Q1 2025, and shifted to a non-GAAP net loss of $1.3 million from a non-GAAP net income of $2.9 million in the prior year period. Adjusted EBITDA fell significantly to $2.0 million from $8.2 million.

• Full-Year 2026 Guidance Reaffirmed

  Despite the weaker first-quarter results, Stratasys reiterated its full-year 2026 financial outlook, projecting revenue in the range of $565 million to $575 million, non-GAAP net income of $8 million to $12.5 million, and Adjusted EBITDA of $25 million to $30 million, with positive operating cash flow expected.

• Strategic Progress in Key Markets

  The company highlighted 23% organic growth in Stratasys Direct, driven by drone customers. It also announced TrueDent® CE Class IIA Certification in Europe, expanding its reach in the dental market, and noted a growing pipeline in high-requirement applications, particularly in defense, including the US Department of War's JAMA IV Program.

auto_awesomeAnalysis

Stratasys Ltd. reported a challenging first quarter with a 2.4% year-over-year revenue decline, a widening GAAP net loss, and a shift from non-GAAP net income to a $1.3 million non-GAAP net loss. Adjusted EBITDA also saw a significant reduction. Despite these weaker quarterly results, management reiterated its full-year 2026 financial outlook, projecting sequential improvement and positive non-GAAP net income and Adjusted EBITDA for the full year. This suggests confidence in strategic initiatives, including strong organic growth in Stratasys Direct, new dental certifications, and a building pipeline in the defense sector. Investors will be watching closely for execution on these strategic fronts and the company's ability to achieve its reaffirmed annual targets.